Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. (NASDAQ: NTRA) is a medical laboratories company focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. As a publicly traded issuer on the Nasdaq Stock Market LLC (Nasdaq Global Select Market), Natera files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), which provide insight into its operations, financial condition, and material events.
On this SEC filings page, Stock Titan aggregates Natera’s regulatory documents, such as current reports on Form 8-K. For example, a recent Form 8-K filing describes the company’s release of quarterly financial results and an accompanying investor presentation, and confirms that Natera’s common stock, par value $0.0001 per share, is registered under the symbol NTRA on Nasdaq. These filings help investors understand how test volumes, revenue trends, and other operational metrics relate to Natera’s diagnostic and research activities.
Stock Titan enhances these filings with AI-powered summaries that explain key sections in accessible language, helping users interpret complex disclosures without replacing the original documents. Real-time updates from the SEC’s EDGAR system ensure that new Natera filings are added promptly, whether they involve earnings announcements, significant collaborations, or other reportable events.
Users interested in Natera’s precision medicine business can use this page to review historical and recent filings, track how the company discusses its oncology, women’s health, and organ health portfolios over time, and monitor material developments affecting NTRA. For deeper analysis, AI-generated highlights point to important items within lengthy filings so readers can focus on sections most relevant to their research or investment questions.
Natera, Inc. (NTRA) Form 144 notice reports a proposed sale of 25,527 common shares valued at $4,591,286.22 to be sold on 09/19/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The shares were acquired on 08/08/2024 through previously exercised stock options and paid in cash. The filer discloses multiple recent sales over the past three months, including 10b5-1 program sales: 14,473 shares by Matthew Rabinowitz on 09/18/2025 (gross proceeds $2,607,069.25) and several sales by related trust entities totaling 31,718 shares with combined proceeds reported. The filer certifies no undisclosed material adverse information and notes reliance on Rule 10b5-1 sales where indicated.
Natera, Inc. insider sale notice for common stock. The filer reports a proposed sale of 22,000 common shares through Charles Schwab & Co., with an aggregate market value of $4,237,900 and approximately 137,248,106 shares outstanding, representing about 0.016% of outstanding stock. The shares were originally acquired as founders' shares on 04/30/2012 from the issuer. The form also discloses five prior sales by the same person in July–September 2025 totaling 15,210 shares and gross proceeds shown for each trade. The filer attests no undisclosed material adverse information and includes standard Rule 144 representations.
Natera, Inc. (NTRA) notice reports a proposed sale of 10,000 common shares through Morgan Stanley Smith Barney with an aggregate market value of $1,800,000. The filing lists 137,248,106 shares outstanding, so the block represents about 0.0073% of outstanding stock, indicating a very small ownership fraction being sold. The shares were acquired as a gift on 03/02/2020 from the issuer, and the filing discloses two recent sales in the past three months: 5,000 shares sold on 09/12/2025 for $852,707 and 1,718 shares sold on 07/28/2025 for $240,190.65. The filer certifies they are not aware of any undisclosed material adverse information.
Natera, Inc. (NTRA) Form 144 notice reports a proposed sale of 14,473 common shares through Morgan Stanley Smith Barney on 09/18/2025 with an aggregate market value of $2,538,998.39. The filer acquired these shares on 08/08/2024 by exercising stock options and paid cash for the 14,473 shares. The filing shows recent sales by related parties: 5,000 shares sold on 09/12/2025 for $852,707.35 and 1,718 shares sold on 07/28/2025 for $240,190.66. Outstanding shares are listed as 137,248,106, which provides context for the relative size of the proposed sale.
Natera insider reported a minor disposition of common stock via charitable contribution. Solomon Moshkevich, listed as President, Clinical Diagnostics and an officer of Natera, executed a gift of 300 shares of Natera common stock on 09/15/2025, recorded as a disposition at $0 per share. After the reported transaction he beneficially owns 120,559 shares directly. The Form 4 was signed by an attorney-in-fact on 09/17/2025 and notes the sale was a charitable contribution.
Natera, Inc. (NTRA) Form 144 filed to report a proposed sale of 9,210 shares of common stock through Charles Schwab & Co., Inc., with an aggregate market value reported as $1,620,445.00 and an approximate sale date of 09/17/2025 on NASDAQ. The filer indicates the shares were acquired on 04/12/2021 from the issuer by various methods and dates. The filing also discloses multiple prior small sales by the same person during the past three months: sales on 07/02/2025, 07/16/2025, 08/08/2025, and 08/11/2025 totaling reported gross proceeds shown per sale.
Matthew Rabinowitz, Executive Chairman and Director of Natera, Inc. (NTRA), reported sales of common stock under a pre-established trading plan. On 09/12/2025 the filing shows a total of 5,000 shares sold (4,500 and 500 shares) at prices reported as a weighted average of $170.3083 for one block and $172.64 for the other, with the larger block sold at prices ranging from $170.00 to $170.93. The Form states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2025.
The filing lists 2,360,852 shares beneficially owned directly following the reported transactions. It also records indirect holdings attributed to a spouse of 25,500 and 25,000 shares on separate lines. The Form 4 was signed by an attorney-in-fact on 09/16/2025.
Natera, Inc. (NTRA) director and CEO Steven Leonard Chapman reported sales of 5,079 shares of Natera common stock on 09/02/2025 executed under a Rule 10b5-1 trading plan. The sales are reported on three lines with weighted-average prices disclosed in ranges: $164.93–$165.7750, $165.97–$166.90, and $167.41–$168.28. After these transactions Mr. Chapman beneficially owned 158,514 shares. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person and discloses that the trades were made pursuant to a plan adopted December 11, 2023 and amended December 2, 2024.
Natera, Inc. (NTRA) insider sale under 10b5-1 plan. On 09/02/2025 Solomon Moshkevich, President, Clinical Diagnostics, reported three open-market sell transactions totaling 3,000 shares executed under a Rule 10b5-1 plan adopted on 11/26/2024. The sales were reported at weighted-average prices of $165.6862, $166.39, and $167.7145, with underlying per-trade price ranges of $165.09–$168.21. Beneficial ownership reported after the trades declined from 122,569 to 120,859 shares across the transactions. The Form 4 was signed by an attorney-in-fact on 09/05/2025.
Natera director Rowan E. Chapman reported multiple equity transactions in Form 4. On 06/27/2025 the reporting person received 2,143 RSUs that vest in full on 06/12/2026 (accelerated vesting on a change in control) and 271 RSUs of which 25% vested immediately and the remainder vest in three equal quarterly installments. On 07/25/2025 an additional 149 RSUs were issued in lieu of quarterly director retainer fees and were fully vested at issuance. On 08/28/2025 the reporting person sold 2,750 shares at $166.99 per share. After these transactions the reporting person beneficially owned 6,015 shares. The Form 4 was signed by an attorney-in-fact on 09/02/2025.